On June 2, BeOne Medicines fell 3.85% in regular trading, trading at 165.7 HKD/share, with trading volume of 222 million HKD.

On the news front, Baker Bros. Advisors LP, an affiliated fund of board directors Julian Baker and Felix Baker, recently sold approximately $190 million worth of shares. While the fund retains board seats and holds approximately 8.21% of shares outstanding, the substantial reduction has weighed on market sentiment. Additionally, the Hong Kong-listed innovative drug sector has been in correction mode for over eight months since last September, with the sector benchmark index declining more than 30% during this period.

Within the Biotechnology sector, the broader sell-off continued today. AKESO fell 3.54%, 3SBIO dropped 7.02%, Innovent Biologics declined 3.89%, SKB Bio lost 6.57%, and Remegen fell 4.91%. As a heavyweight leader in the sector, BeOne Medicines remains under sustained downward pressure from both company-specific and sector-wide headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)